Loading organizations...
§ Private Profile · Paris, France
Bioproduction platform developer using plants to produce recombinant proteins and biomolecules for biopharma and cosmetics.
Founded in 2020 by Alexandre Reeber and Chouaib Meziadi, Core Biogenesis develops an advanced bioproduction platform using plants as biofactories to manufacture recombinant proteins and biomolecules. The enterprise initially focused on biopharmaceutical applications, engineering specific growth factors designed for cell therapies targeting neurodegenerative diseases and cancers, alongside inputs for cultivated meat production. Recently, the firm expanded its product portfolio into the cosmetics sector by launching specialized skincare actives named Peauforia FGF-2 and Peauvita EGF in September 2024. The organization currently supplies its proprietary biomolecules to approximately thirty confidential clients, which include large pharmaceutical corporations and emerging cultivated protein manufacturers. To support its technology development and commercialization efforts, the company secured a seed round of 3,160,000 dollars followed by a Series A financing of 10,500,000 dollars backed by investors XAnge, Entrepreneurs First, and Plug and Play.
Core Biogenesis has raised $13.5M across 2 funding rounds.
Core Biogenesis has raised $13.5M in total across 2 funding rounds.
Core Biogenesis has raised $13.5M across 2 funding rounds. Most recently, it raised $10.5M Series A in July 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 29, 2022 | $10.5M Series A | XAnge | Blue Horizon, Thia Ventures | Announced |
| Dec 1, 2020 | $3M Seed | XAnge | Alchemist Accelerator, EFounders, Benoit Charles Lavauzelle, Clement Benoit, Frederic Montagnon, Julien Romanetto, Nicolas Steegmann, Oleg Tscheltzoff, Thibaud Elziere, Entrepreneur First, Plug And Play | Announced |
Core Biogenesis has raised $13.5M in total across 2 funding rounds.
Core Biogenesis's investors include XAnge, Blue Horizon, Thia Ventures, Alchemist Accelerator, eFounders, Benoit Charles- Lavauzelle, Clement Benoit, Frederic Montagnon, Julien Romanetto, Nicolas Steegmann, Oleg Tscheltzoff, Thibaud Elziere.
Core Biogenesis is a biotechnology company founded in 2020 and based in Paris, France (with operations in Illkirch-Graffenstaden), specializing in plant-based bioproduction of recombinant proteins and peptides for regenerative medicine, cell therapy, stem cell research, and longevity skincare.[1][2][3] It produces growth factors and cytokines to enhance cell culture performance in 3D, large-scale, and suspension settings, serving biopharma, research, skincare, and wellness sectors with sustainable, scalable alternatives to traditional methods.[1][2] The company solves key challenges in bioproduction by using plants as biofactories for cost-effective, ethical, and consistent proteins, backed by a $26.7M total funding including a $10.5M Series A in 2022, and reported revenue of $6.3M with 11-50 employees.[3][6]
Core Biogenesis emerged in 2020 amid rising demand for sustainable bioproduction in biotech, leveraging proprietary plant-based platforms to address limitations in recombinant protein manufacturing.[1][2][3] While specific founders are not detailed in available sources, the company quickly gained traction through its patented technology targeting proteins to plant oleosomes for improved stability, launching a production facility for growth factors and cytokines in early 2023 after securing $10.5M in Series A funding announced in July 2022.[2][3] This funding milestone supported scaling its ultra-scalable platform, positioning it as part of Entrepreneurs First's portfolio and enabling early products for cell culture and bioprocessing.[3][5]
Core Biogenesis rides the wave of sustainable biotech and regenerative medicine, capitalizing on trends in cell/gene therapies, longevity skincare, and decarbonized manufacturing amid global pushes for ethical, scalable bioproduction.[1][2][4] Timing is ideal post-2020 biotech boom, with market forces like rising demand for animal-free proteins (driven by regulatory pressures and ESG investing) favoring its plant platform over traditional methods.[3][4] It influences the ecosystem by enabling cheaper, greener building blocks for startups in stem cells, cultivated meat, and anti-aging—part of a shift seen in peers like ORF Genetics—while its Entrepreneurs First backing amplifies network effects in Europe's biotech hub.[1][5]
Core Biogenesis is poised to expand its plant biofactory globally, potentially launching more peptides for longevity and personalized medicine as funding scales production beyond 2023 facilities.[2][3] Trends like AI-optimized bioproduction, stricter sustainability regs, and explosive growth in cell therapies (projected to hit $50B+ markets) will propel it, evolving its role from niche supplier to key enabler in regenerative tech.[1][6] Watch for partnerships in skincare and food tech, solidifying its edge in a crowded biotech field—ultimately redefining protein manufacturing as sustainable and accessible from the ground up.[2][4]